Menu

HIV Quickly Invades the Brain

The virus that causes AIDS can replicate and mutate in the brain as early as four months after initial infection, according to a new study.

Mar 30, 2015
Jenny Rood

NIAID/NIH, SETH PINCUS, ELIZABETH FISCHER, AUSTIN ATHMANHIV enters the brain early in the course of infection and begins to evolve separately from the blood-based viral population as early as 140 days after initial infection, according to a study published last week (March 26) in PLoS Pathogens.

Researchers from the University of North Carolina, Chapel Hill, the University of California, San Francisco, and Yale analyzed cerebral spinal fluid and blood from 72 HIV-positive patients who were not being treated with antiretroviral therapy (ART). The scientists found that 30 percent of the patients either had replicating viruses or signs of inflammation in their spinal fluid, and that these symptoms persisted for varying amounts of time in 16 percent of the patients, suggesting an ongoing infection.

The researchers also sequenced the viral genomes from approximately half of the patients. From five months after infection to the two-year end point of the study, 20 percent of those 33 patients had developed mutations in the population of virus residing in the brain that differed from the blood-based virus.

“The implication is that there’s a specific infection of the brain rather than HIV just being carried in the blood and passing through the brain,” study coauthor Serena Spudich of Yale University told The Atlantic. HIV is already known to cause cognitive impairment, leading to HIV-associated dementia in one-third of patients who are not on ART. A genetically distinct viral population in the brain could also make the disease more difficult to treat, since some medications may not be able to target an infection there.

“This shows that viral replication and inflammation can occur early in infection, with the concern being that the damage caused could be irreversible,” study coauthor Ronald Swanstrom of the University of North Carolina added in a statement, although future research will be needed to determine if the brain infection is truly untreatable.

 

July 2019

On Target

Researchers strive to make individualized medicine a reality

Marketplace

Sponsored Product Updates

IDT and Washington University join forces to increase access to the latest NGS technologies
IDT and Washington University join forces to increase access to the latest NGS technologies
As part of its commitment to advocate for the genomics age, Integrated DNA Technologies (IDT) aims to lower the barriers to access the latest NGS technologies.
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Launches Bio-Plex Pro Human Immunotherapy Panel 20-plex Multiplex Assay, a targeted tool for researching signaling networks in Immunotherapy Research
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) July 15, 2019 announced the launch of its Bio-Plex Pro Human Immunotherapy Panel 20-plex, a multiplex immunoassay that offers a targeted approach for Immunotherapy Research.
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
DeNovoMAX - NRGene's new genomics tool to meet a major agbio need:
NRGene has launched a new product that aims to empower breeding and maximize agricultural yield as part of the Denovo assembly product suite offered by the company.
Overcoming the Efficiency Challenge in Clinical NGS
Overcoming the Efficiency Challenge in Clinical NGS
Download this white paper to see how an ECS lab serving a network of more than 10,000 healthcare providers integrated QIAGEN Clinical Insight (QCI) Interpret to significantly reduce manual variant curation efforts and increase workflow efficiency by 80%!